Toumai is MicroPort MedBot's four-arm laparoscopic surgical robot and the most credible Chinese challenger to Intuitive's da Vinci. It has passed 200 global installations and over 300 cumulative orders, and in March 2026 it was used for the first remote surgery performed from the UK — a surgeon operating from London on a patient 2,400 km away in Gibraltar. If you are benchmarking robotic-surgery capital spend, Toumai is the system that resets the price floor.
A note on the figures below: surgical robots are never sold at a public list price. Every deal is a negotiated tender shaped by configuration, service term, training, and volume commitments. The numbers here come from published government-procurement records and company disclosures, not from a price sheet. Note also that the verified award figures below are 2024 benchmarks in a market the same sources describe as an active price war — treat them as a calibrated floor for your own tender, not as today's quote.
The one verified Toumai price
The most useful public data point is a real, awarded contract rather than an estimate:
| Item | Figure |
|---|---|
| System | Toumai four-arm laparoscopic surgical robot |
| Awarded tender price | **RMB 11,995,800** (~USD 1.65M) |
| Source | Shanghai Government Procurement Network, July 2024 |
| Significance | A record-low award price for a domestic four-arm laparoscopic robot at the time |
That single figure is worth more than a dozen vendor estimates, because it is what a hospital actually paid under public procurement rules. For budgeting in 2026, RMB 10–12M (roughly $1.4–1.7M) is the defensible band for a Toumai four-arm system inside China.
Be careful with a second number that circulates widely. In November 2024, Ganzhou Municipal Hospital published a RMB 7.5M procurement for an endoscopic surgical instrument control system, reported as a new low. That RMB 7.5M was a budget ceiling, not an award price, and no brand was confirmed — it is not a Toumai price and should not be quoted as one.
How Toumai prices against the alternatives
| System | Indicative capital price | Notes |
|---|---|---|
| **Toumai (four-arm, MicroPort MedBot)** | ~RMB 12.0M / ~$1.65M | Verified 2024 Chinese tender award |
| da Vinci 5 (Intuitive) | ~$2.0M–$2.5M | Intuitive publishes no list price; secondary estimates |
| da Vinci Xi (Intuitive) | ~$1.42M average selling price | Reported Q4 ASP, prior generation |
| Legacy da Vinci (Xi and earlier) | Several hundred thousand to $1M+ | Refurbished and prior-gen units |
| Shurui single-port (Chinese) | ~RMB 19.97M / ~$2.75M | Ruijin Hospital award, June 2024 (converted at ~7.25 RMB/USD) |
Two things fall out of this table. First, Toumai undercuts a new da Vinci 5 meaningfully — though note the Toumai figure is an awarded Chinese tender price while the da Vinci numbers are US-market estimates, so the two are not like-for-like. Either way it is not a budget device — this is a multi-million-dollar capital purchase either way. Second, single-port systems cost more than four-arm systems, not less. If someone quotes you a single-port robot at four-arm money, check what is actually in the configuration.
The purchase price is the smaller half of the bill
This is the part most capital plans get wrong. Approximately 84% of Intuitive's revenue is recurring (FY2025: $8.47B of $10.06B) — instruments, accessories, and service, not system sales. The economics of the category are built on consumables, and the same structure applies to Chinese entrants.
What that means in practice: instrument arms are life-limited and priced per use, so a program running 300 cases a year can spend more on consumables over five years than it spent on the robot. Before comparing two systems on sticker price, get both vendors to quote cost per case at your projected volume, plus the annual service contract. A system that is $400k cheaper up front can lose that advantage in under three years on instrument pricing alone.
The market is also moving away from pure capital purchase. Pay-per-click and leasing structures shift the robot from capex to opex with little money down, which changes the comparison entirely — a lower-priced system is worth less if its per-procedure fee is higher.
What to confirm before you buy
Regulatory access is the first gate, not the price. Toumai holds NMPA approval in China, including for the Toumai SP single-port system. Approval status outside China varies by jurisdiction and is the item to verify first — a favorable price is irrelevant if the system cannot be registered in your market.
Beyond that, the questions that actually move the number:
- Cost per case at your projected annual volume, with the instrument life spelled out
- Service contract: annual cost, uptime guarantee, on-site response time, and local parts inventory
- Training and proctoring: how many surgeons are covered, and who pays for the ramp-up cases
- Telesurgery capability: Toumai's remote-surgery record is a genuine differentiator, but confirm what the network and regulatory requirements are in your region
- Installed base near you: with 200+ installations, ask for a reference site running comparable case mix and call them
Bottom line
Budget $1.4–1.7M for a Toumai four-arm system based on verified Chinese tender data, against roughly $2.0–2.5M for a new da Vinci 5. That gap is real, but it is a fraction of what you will spend on instruments and service over the life of the program. Price the consumables and the service contract before you price the robot — and confirm regulatory approval in your market before you do either.
Sources
- Shanghai Government Procurement Network (July 2024): Toumai MT-1000 four-arm laparoscopic robot awarded to Shanghai First People's Hospital at RMB 11,995,800 — https://yixie168.com/mobile/news/202407/30/907.html (secondary coverage: https://finance.sina.com.cn/roll/2024-11-11/doc-incvsyzf7226022.shtml )
- MicroPort MedBot: Toumai passes 200 global installations — https://www.medbotsurgical.com/en/news/281.html
- MicroPort MedBot: Toumai surpasses 300 global orders (Feb 2026) — https://www.tipranks.com/news/company-announcements/microport-medbots-toumai-surgical-robot-surpasses-300-global-orders-as-remote-surgery-push-accelerates
- The London Clinic: first remote robotic telesurgery performed from the UK (patient in Gibraltar), March 2026 — https://www.thelondonclinic.co.uk/news-articles/the-london-clinic-first-uk-remote-robotic-telesurgery
- MicroPort MedBot: Toumai SP single-port NMPA approval — https://www.medbotsurgical.com/en/news/256.html
- Intuitive Surgical FY2025 Form 10-K: recurring revenue composition — https://www.sec.gov/Archives/edgar/data/1035267/000103526726000010/isrg-20251231.htm
- MedTech Dive: da Vinci 5 launch plan and Xi average selling price — https://www.medtechdive.com/news/intuitive-da-vinci-5-robot-launch-plan/710547/
- American College of Surgeons Bulletin (February 2026): robotic-surgery cost structure, recurring revenue share, and pay-per-click models — https://www.facs.org/for-medical-professionals/news-publications/news-and-articles/bulletin/2026/february-2026-volume-111-issue-2/cost-of-robotic-surgery-remains-complex-equation/
